Medpace bucks negative IPO trend as it raises high end of its range

Medpace has raised $161 million in its initial public offering, the top end of the CRO’s desired range, despite persistent headwinds for other sectors including biotech.

The Cincinnati, OH-based company, which made $332 million in the previous financial year, had been owned by investment firms Cinven and MPI, who held about 75% and 25% of the company respectively.

This exit to the public markets is a fast turnaround for Cinven, which bought Medpace from private equity firm CCMP Capital Advisors back in 2014 for around $900 million.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The CRO sold 7 million shares at $23--the high end of the range of $20 to $23. Medpace said in a statement that it plans to list on the Nasdaq under the symbol "MEDP."

The company added that it intends to “use the net proceeds of this offering to repay a portion of its outstanding borrowings under its senior secured term loan facility.”

- check out the release

Related Articles:
Medpace seeks $151M IPO; says CRO industry worth $31B by decade’s end
Medpace seeking $1B public offering: Reuters


Suggested Articles

The FDA warned healthcare providers about cybersecurity vulnerabilities within certain clinical information systems made by GE Healthcare.

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

What a difference a day makes in biotech.